The updated COVID shots from Pfizer-BioNTech and Moderna target the current KP.2 strain of SARS-CoV-2, a descendant of the highly contagious Omicron subvariant JN.1.
In a phase 3 clinical trial, researchers have found that the new non-hormonal drug, Elinzanetant, could reduce the frequency and severity of vasomotor symptoms in menopausal women.
Medical Daily will always protect your security and privacy. Please read our detailed Privacy Policy
Please do not reply to this email. Click here to adjust your notification preferences or unsubscribe.
